Submit Manuscript  

Article Details


CS5931, A Novel Marine Polypeptide, Inhibits Migration and Invasion of Cancer Cells Via Interacting with Enolase 1

[ Vol. 13 , Issue. 3 ]

Author(s):

Shuonan Su, Huanli Xu, Xiaoliang Chen, Gan Qiao, Ammad A. Farooqi, Ye Tian, Ru Yuan, Xiaohui Liu, Cong Li, Xiao Li, Ning Wu and Xiukun Lin*   Pages 360 - 367 ( 8 )

Abstract:


Background: CS5931, a novel marine peptide, was extracted and purified from the sea squirt Ciona savignyi. Our previous studies showed that recombinant CS5931 can significantly inhibit tumor growth both in vitro and in vivo. However, its molecular targets have not been elucidated.

Methods: The target of the recombinant CS5931 was identified by pull-down/SDS-PAGE/MS approaches and confirmed by Western blot and surface plasmon resonance analysis. Transwell experiments were used to detect whether the recombinant CS5931 inhibited cancer migration and invasion via enolase 1. Dot blotting analysis was used to detect the effect of CS5931 on the interaction of enolase 1 and plasminogen, as well as enolase 1 and uPA/uPAR.

Results: Enolase 1 was identified as the molecular target interacting with the recombinant CS5931. Transwell experiment showed that the recombinant CS5931 was able to inhibit migration and invasion of HCT116 cells and enolase 1 overexpression reversed the effects of the recombinant CS5931 on migration and invasion of cancer cells. Dot blotting analysis revealed that the recombinant CS5931 interfered with the interaction among enolase 1 and plasminogen as well as enolase 1 and uPA/uPAR.

Conclusion: Our present study showed that the recombinant CS5931 could inhibit tumor invasion and matastasis via interacting with enolase 1, suggesting that the new marine polypeptide CS5931 possesses the potential to be developed as a novel anticancer agent.

Keywords:

Enolase1, migration and invasion, protein-protein interaction, recombinant CS5931.

Affiliation:

Department of Pharmacology, Capital Medical University, Beijing 100069, Department of Pharmacology, Capital Medical University, Beijing 100069, School of medicine, Shanxi Datong University, Datong 037009, Department of Pharmacology, Capital Medical University, Beijing 100069, Institute of Biomedical and Genetic engineering, Islamabad, Department of Pharmacology, Capital Medical University, Beijing 100069, Department of Pharmacology, Capital Medical University, Beijing 100069, Department of Pharmacology, Capital Medical University, Beijing 100069, Department of Pharmacology, Capital Medical University, Beijing 100069, Department of Pharmacology, Capital Medical University, Beijing 100069, Institute of Oceanology, Chinese Academy of Science, Qingdao 266071, Department of Pharmacology, Capital Medical University, Beijing 100069



Read Full-Text article